Search Results

Elutia Inc. (Nasdaq: ELUT) (“Elutia” or the “Company”), a pioneer in drug-eluting biomatrix products, today announced that its Antibiotic-Eluting BioEnvelope, EluPro® (referred to as CanGaroo®RM during development), has received clearance from the U.S. Food and Drug Administration (FDA).

Elixir Medical’s DynamX Sirolimus-Eluting Coronary Bioadaptor System Granted FDA Breakthrough Device Designation for the Treatment of Symptomatic Ischemic Heart Disease.

Elutia Inc. (Nasdaq: ELUT) today announced it has submitted a 510(k) premarket notification to the U.S. Food and Drug Administration (FDA) for its next-generation drug-eluting biomatrix product, CanGarooRM®.

ChromaTan is excited to announce an alliance with Batavia Biosciences, a leading contract development and manufacturing organization, for the development and integration of ChromaTan’s BioRMBTM continuous counter-current elution technology into Batavia’s AAV HIP-Vax® manufacturing platform.

Elixir Medical, a developer of transformative technologies to treat cardiovascular and peripheral disease, announced two-year results from the BIOADAPTOR Randomized Controlled Trial, comparing the DynamX® Coronary Bioadaptor System to standard of care Resolute OnyxTM Drug-Eluting Stent from 34 centers in Japan, Europe, and New Zealand.

ChromaTan, a bioprocessing and biotools advanced biomanufacturing technology platform development company, is excited to announce the award of NIH IIB grant of $2M from the National Institute of General Medical Sciences, for the development and integration of ChromaTan’s novel BioRMB™ single-use, column-free, steady-state continuous counter-current elution technology for manufacturing AAVs.